The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
- 4
- 2016-2016
Filter Results (128)
-
Research Grant, 2016Saliva Alpha-synuclein Levels in LRRK2 Mutation Carriers
Study Rationale:
Biomarkers (markers of disease activity) are needed to help determine a diagnosis of Parkinson's disease (PD) and to monitor disease progression. Reduced cerebrospinal fluid (baths... -
Research Grant, 2016Chronic Effects of Low Frequency Deep Brain Stimulation on Aspiration, Freezing of Gait and Other Axial and Motor Symptoms in Parkinson's Disease
Study Rationale:
Our recent study (Xie et al., Neurology. 2015;84:415-420) found that 60Hz stimulation, compared to the traditional 130Hz, decreased aspiration frequency and swallowing difficulty... -
Biomarkers Across Neurodegenerative Diseases, 2016Homo- and Hetero-aggregates as Biomarkers in Neurodegenerative Disorders
Study Rationale:
Neurodegenerative disorders like Alzheimer's and Parkinson's disease often have overlapping symptoms, which can make it difficult to differentiate them from one another in the clinic... -
Target Advancement Program, 2016Identifying Enzymes to Stimulate Alpha-synuclein Degradation
Study Rationale:
Rab GTPases, a family of small molecules that guide protein movement around cells, are linked to Parkinson's disease (PD). We have identified a group of Rabs with potential roles in... -
Research Grant, 2016Defining Structural Forms of Alpha-synuclein Responsible for Key Features Associated with Parkinson's Disease
Study Rationale:
The alpha-synuclein pre-formed fibril (PFF) model shows promise for modeling many features of Parkinson’s disease (PD). In this model, PFFs induce pathological features and behaviors... -
Research Grant, 2016Therapeutic Effects of XPro1595 on Motor and Non-motor Outcomes in a Pre-clinical Model of Parkinson's disease
Study Rationale:
Studies funded under the 2012 TDI award revealed that peripheral administration of XPro1595 in the 6-OHDA (neurotoxin) pre-clinical model afforded significant neuroprotection against...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.